Sue Gail Eckhardt

Executive

Director

Exelixis, Inc.Syros Pharmaceuticals, Inc.

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 2 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 2 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 1 saleMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (5 ops.)

€1.2M

Latest filing published 29 May 2026 for Exelixis, INC..

Filing timeline

BuySale

Sue Gail Eckhardt

Insider track record

Disclosed buys

Disclosed sells

Signal history

Sue Gail Eckhardt: trading record in brief

Sue Gail Eckhardt filed 5 sales at Exelixis, Inc., worth EUR 1,232,473, median EUR 142,272. The largest, EUR 702,815, dates from June 2, 2025, ahead of EUR 258,082 on February 14, 2025 and EUR 142,272 on February 13, 2026. No purchase appears.

The 13 filings, published from September 19, 2022 to May 29, 2026, split between Exelixis (10) and Syros Pharmaceuticals, Inc. (3), always as Director. They include 7 share grants and one option exercise. Annual volume is 1 filing in 2022 and in 2023, 3 in 2024, 6 in 2025, its highest year, and 2 in 2026. Two filings fall in the last twelve months, one of them a sale.

Filings appear a median of 3 days after the trade. At Exelixis, Christopher J. Senner, Jack L. Wyszomierski and Patrick J. Haley each have 5 open-market trades within 30 days of those of Eckhardt, George Poste 4 and Bob Oliver 3, all in the same direction.